NCT06646978
Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial No drug interventions Not Available Not Available enrolling_by_invitation NCT00720785
Natural Killer Cells and Bortezomib to Treat Cancer treatment 1 completed NCT02790515
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation treatment 2 active_not_recruiting NCT06130787
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy No drug interventions other Not Available recruiting NCT02889003
Second STOP After Pioglitazone Priming in CML Patients treatment 2 unknown_status NCT00320190
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib treatment 2 terminated NCT02381379
Malaysia Stop Tyrosine Kinase Inhibitor Trial treatment 3 unknown_status NCT01667133
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) treatment 1 / 2 completed NCT00481247
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia treatment 3 completed NCT03615105
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors treatment 2 terminated NCT00449761
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase treatment 2 terminated NCT02326311
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response treatment 3 completed NCT04126707
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans treatment 1 completed NCT00538109
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase treatment Not Available completed NCT00428909
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treatment 1 completed NCT00478985
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia No drug interventions treatment Not Available completed NCT01015742
Unrelated Double Umbilical Cord Blood Units Transplantation No drug interventions treatment 2 / 3 unknown_status NCT01592136
Expanded Access Program of Ponatinib Not Available Not Available approved_for_marketing NCT00210119
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response treatment 2 terminated NCT00763763
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive treatment 2 completed NCT02852486
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response other 2 active_not_recruiting NCT00732186
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia treatment 1 withdrawn NCT04260022
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL treatment 1 recruiting NCT00445822
Registration of Children With CML and Treatment With Imatinib No drug interventions Not Available Not Available unknown_status NCT00176930
Stem Cell Transplant for Hematological Malignancy treatment Not Available terminated NCT04384848
The EMPATHY Pilot Study No drug interventions supportive_care Not Available completed NCT05154474
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy No drug interventions Not Available Not Available unknown_status NCT02389920
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib treatment 4 unknown_status NCT00050531
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) treatment 3 completed NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor prevention 2 terminated NCT00488592
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers treatment 2 completed NCT00027144
Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase No drug interventions treatment 1 completed NCT00167167
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia No drug interventions treatment Not Available completed NCT03578367
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treatment 2 active_not_recruiting NCT02222272
Effect of 2nd Gen TKI in CML No drug interventions Not Available Not Available completed NCT02363868
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population No drug interventions Not Available Not Available completed NCT01066468
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. Not Available 1 terminated NCT01605981
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. treatment 4 withdrawn NCT00482703
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia treatment 1 / 2 completed NCT00455221
Safety Assessment of a Multipeptide-gene Vaccine in CML No drug interventions treatment 1 completed NCT00067002
Randomized Double Cord Blood Transplant Study treatment 2 completed NCT00034684
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) No drug interventions treatment 1 / 2 completed NCT02890784
Dasatinib Holiday for Improved Tolerability treatment 3 completed NCT00298987
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate treatment 2 completed NCT02086487
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy treatment 4 terminated NCT03746054
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality No drug interventions prevention 3 unknown_status NCT03849651
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies treatment 2 active_not_recruiting NCT00538447
Prospective Database for Chronic Myelogenous Leukemia No drug interventions health_services_research Not Available unknown_status NCT00058747
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ treatment 2 terminated NCT02733445
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib Not Available Not Available completed NCT00433745
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy No drug interventions treatment 2 completed NCT00040105
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia treatment 1 completed NCT05963061
Chronic Myeloid Leukemia (CML) Real-Life Database No drug interventions Not Available Not Available recruiting NCT02973711
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML treatment 1 / 2 withdrawn NCT00406393
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) treatment 3 completed NCT01660607
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell No drug interventions treatment 1 / 2 completed NCT00539656
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers No drug interventions treatment 1 / 2 terminated NCT00759837
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Not Available 1 completed NCT00306332
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation No drug interventions treatment 3 terminated NCT02061800
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant treatment 1 / 2 active_not_recruiting NCT00114959
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) treatment 2 terminated NCT00186342
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies No drug interventions treatment Not Available completed NCT02543749
DC Vaccination in CML No drug interventions treatment 1 / 2 terminated NCT03515018
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients treatment 3 unknown_status NCT06514534
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. treatment 2 not_yet_recruiting NCT00566696
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies treatment 2 completed NCT04709731
Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia treatment 2 not_yet_recruiting NCT02627573
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT prevention 2 terminated NCT00264160
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy treatment 2 / 3 completed NCT00246662
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies treatment 1 completed NCT00167180
Post Transplant Donor Lymphocyte Infusion treatment 2 terminated NCT05143840
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase treatment 2 recruiting NCT02269267
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) treatment 2 completed NCT03481868
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors No drug interventions other Not Available recruiting NCT01050946
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit No drug interventions treatment 2 terminated NCT01761695
Chronic Myelod Leukemia Registry at Asan Medical Center No drug interventions Not Available Not Available terminated NCT00186823
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT04943757
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies treatment 2 completed NCT06236724
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. treatment 2 recruiting NCT03874858
De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination treatment 2 active_not_recruiting NCT05115630
Off-the-shelf NK Cells + SCT for Myeloid Malignancies treatment 1 / 2 recruiting NCT05362773
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies No drug interventions treatment 1 recruiting NCT05800210
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases No drug interventions treatment 2 recruiting NCT06398457
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies treatment 0 recruiting NCT01805843
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia No drug interventions Not Available Not Available completed NCT05260203
MargheRITA (Remote Intelligence for Therapeutic Adherence) No drug interventions supportive_care Not Available completed NCT01761890
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib No drug interventions Not Available Not Available unknown_status NCT00522990
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias treatment 1 / 2 terminated NCT05236764
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion No drug interventions treatment Not Available recruiting NCT00435864
Natural Killer Index From Hematopoietic Stem Cell Graft No drug interventions health_services_research Not Available completed NCT04048564
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) No drug interventions Not Available Not Available completed NCT00845221
Glivec in Pediatric Chronic Myeloid Leukemia (CML) Not Available 4 completed NCT00511121
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) treatment 2 terminated NCT00815321
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy No drug interventions treatment 2 completed NCT03326921
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant treatment 1 suspended NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia treatment 1 / 2 recruiting NCT03795779
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies treatment 0 unknown_status NCT05605379
CML Pediatric ITK Response According to Molecular Identification at Diagnosis No drug interventions Not Available Not Available recruiting NCT06092879
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France No drug interventions Not Available Not Available recruiting NCT01606579
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies treatment 1 / 2 completed NCT01114087
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility treatment Not Available completed NCT01903733
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 Not Available Not Available completed NCT02016833
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity No drug interventions Not Available Not Available completed NCT00593554
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies treatment 2 terminated NCT03678454
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium No drug interventions Not Available Not Available completed NCT04595851
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications No drug interventions health_services_research Not Available terminated NCT01490853
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy Not Available Not Available completed NCT01866553
Nilotinib Plus Pegylated Interferon-α2b in CML treatment 2 terminated NCT00352677
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia treatment 1 completed NCT00257647
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) No drug interventions Not Available Not Available completed NCT02011945
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia treatment 1 completed NCT01223898
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib other 1 completed NCT01650805
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) treatment 3 terminated NCT00895297
Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia treatment 2 terminated NCT02709083
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia treatment 2 terminated NCT04167683
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No drug interventions Not Available Not Available recruiting NCT03625583
The Hong Kong CML Registry No drug interventions Not Available Not Available unknown_status NCT06355583
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial No drug interventions prevention 2 not_yet_recruiting NCT00067028
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) treatment 2 completed NCT01749111
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis prevention 3 terminated NCT04605211
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors No drug interventions supportive_care Not Available completed NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination No drug interventions treatment 1 / 2 unknown_status NCT06148493
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database No drug interventions Not Available Not Available completed NCT00905593
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Not Available Not Available approved_for_marketing NCT05619978
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients No drug interventions Not Available Not Available completed NCT02767388
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery No drug interventions Not Available Not Available completed NCT04156256
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies No drug interventions treatment 0 unknown_status NCT02057185
Occupational Status and Hematological Disease No drug interventions Not Available Not Available completed NCT05701215
Venetoclax After TKI to Target Persisting Stem Cells in CML treatment 2 recruiting NCT03696537
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT treatment 1 terminated NCT04991532
Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells No drug interventions Not Available Not Available unknown_status NCT00001432
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies No drug interventions Not Available Not Available completed NCT00219752
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years treatment 2 completed NCT02317159
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia treatment 4 unknown_status NCT00513175
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia No drug interventions Not Available Not Available completed NCT00570999
Palifermin After Haploidentical PBSCT treatment 2 withdrawn NCT00858806
Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy treatment 2 completed NCT06390306
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP Not Available Not Available not_yet_recruiting NCT01564836
Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib No drug interventions treatment Not Available unknown_status NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML treatment 2 not_yet_recruiting NCT01578213
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients other 4 completed NCT00145613
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies No drug interventions treatment 2 completed NCT00988013
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies No drug interventions treatment Not Available completed NCT00146913
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year Not Available 2 unknown_status NCT00349518
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL treatment 2 / 3 withdrawn NCT01200017
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant No drug interventions Not Available Not Available no_longer_available NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT04626024
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population treatment 2 recruiting NCT00965224
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma No drug interventions treatment 2 unknown_status NCT00302016
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia Not Available Not Available no_longer_available NCT05611216
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation No drug interventions Not Available Not Available completed NCT03509896
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) No drug interventions Not Available Not Available completed NCT01275196
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients treatment 3 completed NCT02890758
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 treatment 1 completed NCT03353558
Sleep Assessment in CML No drug interventions Not Available Not Available unknown_status NCT01819558
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy No drug interventions treatment 1 / 2 completed NCT04104035
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response No drug interventions Not Available Not Available unknown_status NCT05400122
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer treatment 1 recruiting NCT02398825
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib treatment 2 unknown_status NCT00947830
Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia No drug interventions Not Available Not Available completed NCT03885830
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Not Available Not Available completed NCT01220648
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) treatment 1 completed NCT01549548
Compassionate Use Ponatinib Not Available Not Available no_longer_available NCT00145626
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies treatment 2 completed NCT00219726
Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation treatment 2 completed NCT00852566
Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia treatment 2 completed NCT02885766
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene treatment 1 / 2 unknown_status NCT01167166
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) treatment 1 / 2 completed NCT00219765
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients treatment 1 / 2 terminated NCT02546674
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. treatment 4 completed NCT01400074
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib treatment 3 unknown_status NCT00354120
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant No drug interventions treatment 2 / 3 completed NCT02556931
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies treatment 2 completed NCT00574873
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML treatment 3 completed NCT04043676
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia treatment 2 unknown_status NCT01344876
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies No drug interventions treatment 1 completed NCT06229860
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT02078960
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) other 1 / 2 terminated NCT06042660
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis No drug interventions Not Available Not Available completed NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies No drug interventions treatment 1 / 2 completed NCT05421091
Special Drug Use-results Surveillance of Scemblix Tablets No drug interventions Not Available Not Available completed NCT00327262
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase treatment 3 unknown_status NCT01752062
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors No drug interventions Not Available Not Available unknown_status NCT01572662
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning treatment 2 completed NCT00469729
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy treatment 2 / 3 completed NCT01252589
Patient Reported Outcomes in Chronic Myeloid Leukemia No drug interventions Not Available Not Available completed NCT03906292
Frontline Asciminib Combination in Chronic Phase CML treatment 2 active_not_recruiting NCT00001144
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia No drug interventions treatment 2 completed NCT01207440
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) treatment 2 completed NCT01657604
TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study diagnostic 3 completed NCT02115672
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia treatment 1 / 2 withdrawn NCT00514969
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase treatment 2 completed NCT03075969
Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT03326310
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers treatment 1 recruiting NCT00061581
Experimental Bone Marrow Transplant Protocol No drug interventions treatment 2 completed NCT00493181
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients treatment 2 completed NCT00101595
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia treatment 2 completed NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 recruiting NCT04595955
Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life No drug interventions health_services_research Not Available completed NCT00632255
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment Not Available Not Available completed NCT01244750
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting No drug interventions Not Available Not Available completed NCT01683123
Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT No drug interventions Not Available Not Available completed NCT03018223
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT prevention 1 completed NCT05282108
Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia Not Available Not Available recruiting NCT00827138
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) treatment 1 completed NCT01297543
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia supportive_care 1 / 2 completed NCT02164903
LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients No drug interventions Not Available Not Available unknown_status NCT03228303
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia treatment 0 unknown_status NCT00511303
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia treatment 2 completed NCT02258490
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation Not Available Not Available no_longer_available NCT06233890
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia No drug interventions Not Available Not Available active_not_recruiting NCT00303290
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML treatment 1 completed NCT02810990
Bosutinib in Elderly Chronic Myeloid Leukemia treatment 2 completed NCT00968864
T-cell Depleted Alternative Donor Transplantation No drug interventions treatment 2 terminated NCT01290302
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia treatment 1 completed NCT06453902
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients No drug interventions treatment 2 not_yet_recruiting NCT01270984
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects treatment 1 completed NCT06532084
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen treatment 2 recruiting NCT05753384
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System No drug interventions treatment 3 recruiting NCT01342679
A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib treatment 2 completed NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT01215487
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib No drug interventions Not Available Not Available completed NCT03348033
Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia No drug interventions treatment 1 / 2 unknown_status NCT03540654
Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach No drug interventions Not Available Not Available completed NCT04621851
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation No drug interventions Not Available Not Available unknown_status NCT01169753
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients treatment Not Available terminated NCT05734053
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line No drug interventions Not Available Not Available completed NCT05304377
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia No drug interventions treatment 1 recruiting NCT02253277
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients treatment 1 completed NCT05440747
Treatment Free Remission (TFR) in CML Patients （CML-CP）Study No drug interventions Not Available Not Available not_yet_recruiting NCT01562847
Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib Not Available Not Available unknown_status NCT04769947
Italian Treatment Free Remission Registry No drug interventions Not Available Not Available recruiting NCT04578847
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) treatment 2 active_not_recruiting NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor treatment 2 completed NCT02174445
An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years treatment 3 terminated NCT01698905
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) treatment 2 active_not_recruiting NCT01490983
Telemonitoring Study - for Chronic Myeloid Leukemia (CML) No drug interventions supportive_care Not Available terminated NCT05201183
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies treatment 1 / 2 withdrawn NCT02353728
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy basic_science 2 completed NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML treatment 3 recruiting NCT05768711
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) treatment 2 recruiting NCT04155411
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP treatment 4 unknown_status NCT02707393
Allogeneic Stem Cell Transplantation for Children With CML treatment 2 / 3 completed NCT00573378
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia treatment 2 terminated NCT01254188
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients treatment 3 completed NCT00514488
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) Not Available 3 completed NCT01860456
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study Not Available Not Available recruiting NCT02869256
Regional Central Database Recording of Chronic Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT00267085
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease treatment 2 completed NCT04013685
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies No drug interventions treatment 1 active_not_recruiting NCT06001385
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis treatment 2 recruiting NCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML treatment 3 recruiting NCT00328237
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation No drug interventions treatment 2 unknown_status NCT01627132
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial treatment 2 unknown_status NCT05433532
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients treatment 2 completed NCT00516152
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT treatment 2 completed NCT00481052
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase treatment 2 completed NCT04663100
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence No drug interventions health_services_research Not Available recruiting NCT00750659
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation treatment 2 completed NCT00143559
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies No drug interventions treatment 2 completed NCT02201459
Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients treatment 3 unknown_status NCT00038675
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate treatment Not Available completed NCT02268370
Treatment-free Remission Accomplished With Dasatinib in Patients With CML other 2 unknown_status NCT02895542
Preparatory Work to Assess Adherence to Oral Chemotherapy No drug interventions Not Available Not Available completed NCT03241199
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia treatment 2 unknown_status NCT06508099
Vitamin A and D Supplementation in Allogeneic HCT treatment 2 recruiting NCT04645706
Innate T Cells and TKI Discontinuation No drug interventions Not Available Not Available active_not_recruiting NCT04151706
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML treatment 2 completed NCT01073436
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha No drug interventions Not Available Not Available terminated NCT00866736
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia treatment 2 completed NCT02883036
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT03062436
To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission No drug interventions treatment Not Available unknown_status NCT00464113
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia treatment 1 terminated NCT00162513
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia No drug interventions treatment 1 / 2 withdrawn NCT02422719
Radotinib as 3rd or Later Line Therapy in CP-CML treatment 2 unknown_status NCT04818619
TIGIT in Patients With Chronic Myeloid Leukemia No drug interventions Not Available Not Available unknown_status NCT00375219
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation treatment 2 completed NCT01751919
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) treatment 1 completed NCT00854841
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder Not Available Not Available available NCT03709017
Iclusig PMS in CML or Ph+ALL Patients Not Available Not Available active_not_recruiting NCT03455517
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT00101816
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate treatment 2 completed NCT01795716
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body treatment 1 completed NCT03533816
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide treatment 1 recruiting NCT03996096
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. No drug interventions Not Available Not Available completed NCT01281735
International Chronic Myeloid Leukemia Pediatric Study No drug interventions Not Available Not Available recruiting NCT00152139
Stem Cell Transplantation for Patients With Hematologic Malignancies No drug interventions treatment 3 completed NCT00219739
STI571 ProspectIve RandomIzed Trial: SPIRIT treatment 3 completed NCT04089839
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting No drug interventions Not Available Not Available completed NCT05943522
Asciminib RMP Study No drug interventions Not Available Not Available recruiting NCT02204722
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients treatment 4 terminated NCT02103322
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions treatment 2 / 3 completed NCT05387330
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment No drug interventions Not Available Not Available completed NCT06163430
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia No drug interventions treatment 1 not_yet_recruiting NCT02663648
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders No drug interventions Not Available Not Available withdrawn NCT01394666
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) No drug interventions Not Available Not Available completed NCT02172365
Allogeneic SCT for CML, TKI Failure After TKI Failure No drug interventions Not Available Not Available unknown_status NCT03262974
Effect of Pharmacogenetics on Imatinib Plasma Level and Response No drug interventions Not Available Not Available completed NCT02842320
Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) No drug interventions other Not Available completed NCT02917720
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients treatment 2 active_not_recruiting NCT02129582
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies treatment 1 completed NCT03831776
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis treatment 2 recruiting NCT00101660
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib treatment 2 completed NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression treatment 3 active_not_recruiting NCT01535391
Nilotinib in PH+, BCR-, ABL+ CML Patients treatment 3 completed NCT05476562
Study Conducted Among Patients With CML No drug interventions Not Available Not Available completed NCT00896129
Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy No drug interventions Not Available Not Available completed NCT02896829
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia No drug interventions Not Available Not Available completed NCT00460629
Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation No drug interventions treatment 1 / 2 completed NCT00461929
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib No drug interventions diagnostic 4 terminated NCT04464889
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation No drug interventions treatment 1 withdrawn NCT01188889
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. treatment 1 / 2 withdrawn NCT00710892
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene No drug interventions treatment 1 active_not_recruiting NCT01126892
A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase treatment 3 completed NCT01077544
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) treatment 1 completed NCT00103844
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia treatment 2 completed NCT01068301
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation treatment 1 completed NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection No drug interventions Not Available Not Available recruiting NCT02487069
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy treatment Not Available completed NCT00261846
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias treatment 2 completed NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation treatment 2 active_not_recruiting NCT00786812
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase treatment 4 completed NCT00531310
Reduced Intensity AlloSCT in(CML) With Persistent Disease treatment 2 terminated NCT03193281
KISS Study: Kinase Inhibition With Sprycel Start up treatment 2 active_not_recruiting NCT02448095
Retrospective Evaluation of CML Patients in the National Compassionate Program Not Available Not Available terminated NCT01596114
European Stop Tyrosine Kinase Inhibitor Study No drug interventions treatment 3 completed NCT00469014
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia treatment 2 completed NCT00790855
Bendamustine in Acute Leukemia and MDS treatment 1 / 2 terminated NCT01802450
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase treatment 2 unknown_status NCT05130138
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia No drug interventions other Not Available recruiting NCT00462943
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML treatment 2 completed NCT05286528
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Not Available Not Available completed NCT01804985
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia treatment 2 unknown_status NCT02001818
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia treatment 2 completed NCT05682924
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib No drug interventions Not Available Not Available recruiting NCT01343173
Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib treatment Not Available completed NCT01475110
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib Not Available Not Available completed NCT00390897
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia treatment 4 completed NCT02546375
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands Not Available Not Available completed NCT05893836
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia No drug interventions Not Available Not Available completed NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT01699217
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase No drug interventions Not Available Not Available unknown_status NCT01621724
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study No drug interventions treatment 1 / 2 completed NCT04256317
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML treatment 2 / 3 recruiting NCT01621477
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant treatment 2 terminated NCT01188798
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies treatment 3 completed NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation supportive_care 1 terminated NCT04150471
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients No drug interventions Not Available Not Available unknown_status NCT01045382
MSC and HSC Coinfusion in Mismatched Minitransplants No drug interventions treatment 2 terminated NCT02975115
Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization No drug interventions Not Available Not Available unknown_status NCT00859586
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation No drug interventions treatment Not Available completed NCT00854646
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) treatment 1 completed